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ADAR1: “Editor-in-Chief” of
Cytoplasmic Innate Immunity
Mart M. Lamers, Bernadette G. van den Hoogen and Bart L. Haagmans*
Department of Viroscience, Erasmus MC, Rotterdam, Netherlands
Specialized receptors that recognize molecular patterns such as double stranded
RNA duplexes—indicative of viral replication—are potent triggers of the innate immune
system. Although their activation is beneficial during viral infection, RNA transcribed
from endogenous mobile genetic elements may also act as ligands potentially causing
autoimmunity. Recent advances indicate that the adenosine deaminase ADAR1 through
RNA editing is involved in dampening the canonical antiviral RIG-I-like receptor-, PKR-,
and OAS-RNAse L pathways to prevent autoimmunity. However, this inhibitory effect
must be overcome during viral infections. In this review we discuss ADAR1’s critical role
in balancing immune activation and self-tolerance.
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INTRODUCTION
Our innate immune system has evolved to specifically recognize common molecular patterns
formed as a result of virus replication. These molecular patterns—commonly referred to as
pathogen-associated molecular patterns or PAMPs—are detected by specialized receptors, called
pattern recognition receptors (PRRs), which can rapidly trigger the immune system after ligand
recognition. The replication of virtually all RNA viruses and even dsDNA viruses generates long,
perfectly base-pairing double stranded (ds) RNA intermediates in the cytoplasm. As these dsRNAs
are unusual in the cytoplasm of eukaryotic cells, sensory systems have evolved to detect this
PAMP. These systems then signal the presence of an invading virus, allowing the cell to take
appropriate measures. The main system detecting cytoplasmic dsRNA is the RIG-I-like receptor
(RLR) signaling pathway, named after the first cytoplasmic PRR discovered: retinoic acid-inducible
gene I (1, 2) (RIG-I). Subsequently, another related protein, melanoma differentiation-associated
gene 5 (MDA5), was also found to be involved in dsRNA sensing (3). RLR signaling results in the
production of the antiviral type I interferons (IFN) after PRRs oligomerize along dsRNA filaments.
These oligimerized PRRs recruit the scaffolding proteinmitochondrial activation signaling (MAVS)
and IKK-related kinases and this ultimately results in the phosphorylation of the transcription
factors interferon regulatory factor 3 and 7 (IRF3 and IRF7) (4, 5). These transcription factors
then move to the nucleus where they activate type I IFN promoters leading to the secretion
of IFNs (6). Next, IFN receptor signaling leads to the induction of an antiviral state in the
producing and neighboring cells through the upregulation of interferon stimulated genes (ISGs),
which encode proteins with direct antiviral effector functions, such as protein kinase R (PKR),
2′-5′-oligoadenylate synthetase 1 (OAS1), and RNAse L.
While PRR activation and IFN production are tightly controlled in order to prevent false
triggering of the immune system, it is becoming clear that certain endogenous RNAs can also form
dsRNAs. This includes RNAs transcribed from retrotransposons, such as Alu repeats, and RNAs
originating from the mitochondrial matrix (7). Although these RNAs have the correct structure
to activate PRRs, they appear not to do so under normal circumstances as this would lead to
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severe autoimmune disease (8). This raises the question as to how
cells distinguish between self and non-self nucleic acids.
One process that may be involved in the discrimination
between self and non-self nucleic acids is the editing of RNAs.
RNA editing is a process that regulates and expands the diverse
functions of RNA transcripts and several types of editing have
been characterized so far. Inmammals, two forms of RNA editing
exist, the deamination of cytosines to uracils by members of
the apolipoprotein B mRNA editing enzyme catalytic subunit
(APOBEC) protein family, and the deamination of adenosines
to inosines (A-to-I editing) by the adenosine deaminase acting
on RNA (ADAR) gene family. The cell’s translation and splicing
machineries interpret inosines as guanosines, instead of the
adenosines encoded in the genome (9). This can lead to
non-synonymous substitutions if editing takes place in coding
sequences (10). More importantly, A-to-I substitutions have
the capacity to destabilize dsRNA structures formed between
complementary strands due to the replacement of Watson–Crick
AU base pairs by IU wobble pairs, which are isomorphic with GU
base pairs (11).
Mounting evidence suggests that cytoplasmic antiviral
immunity is controlled at the level of dsRNA recognition by
RNA editing, which appears to play a pivotal role in maintaining
self-tolerance and preventing autoimmunity. Intriguingly,
mutations in the adenosine deaminase ADAR1 can confer
autoimmunity in humans and in mice models (12–17) and
recently ADAR1 has been shown to regulate the canonical RLR-,
PKR-, and OAS-RNAse L pathways. This review summarizes
recent advances related to the function of ADAR1 as a “master
regulator” of cytoplasmic innate immunity and discusses how
the host can still mount an effective antiviral response in the
presence of ADAR1.
ADAR1: RNA EDITOR INDUCED BY IFN
A-to-I editing was originally discovered as enzymatic activity
unwinding dsRNA in Xenopus laevis (18, 19). The protein
responsible for this activity, now known as ADAR1, was termed
an RNA unwindase, and shortly thereafter it was found to
also possess A-to-I editing activity (20–24). In addition, two
other ADARs were discovered, thus comprising a gene family of
three members in mammalian genomes (10, 25–28). Two encode
for ubiquitously expressed enzymes with adenosine deaminase
activity, the IFN-inducible ADAR1 and the constitutively
expressed ADAR2 (24, 29, 30). The third, ADAR3, has not
been shown to possess any enzymatic activity and is expressed
primarily in the brain (30–32). ADAR proteins show extensive
architectural similarity, with centrally located three repeated
copies of a dsRNA-binding domain (dsRBD) and a single
deaminase domain at the C-terminus (Figure 1). The presence
of these dsRBDs underlines that ADAR activity is directed
toward dsRNA.
ADAR1 is expressed to higher levels than the other ADARs
and it is responsible for the majority of editing activity (30).
The protein encoded by this gene exists in two forms that are
generated from alternative exon 1 structures that initiate from
FIGURE 1 | The domain architecture of ADAR1 isoforms p150 and p110.
NES, nuclear export signal; dsRBD, double-stranded RNA binding domain;
NLS, nuclear localization signal.
different promoters (33). A small isoform (p110) is expressed
constitutively while a larger isoform (p150) is upregulated in
response to IFN. The p110 isoform is a truncated version of
p150, lacking one Z-DNA binding domain at the N-terminus,
which contains a nuclear export signal (NES) (33, 34) (Figure 1).
Therefore, p110 is almost exclusively found in the nucleus while
p150 is largely expressed in the cytoplasm (35–38). A bimodal
nuclear localization signal (NLS) flanking the third dsRBD
mediates nuclear import via transportin-1 (39).
ADAR1 BLOCKS RIG-I-LIKE RECEPTOR
SIGNALING
The promoter responsible for p150 expression possesses
a consensus interferon-stimulated response element (ISRE)
characteristic of ISGs (33, 35, 40). The discovery of this element
promised an important role for ADAR1 in the immune response
soon after the protein was discovered. The importance of ADAR1
for survival was already recognized early on as Adar1−/− mice
die by embryonic day 11.5–14 with widespread apoptosis and
cell death of liver hemotopoietic cells (41–43). Clues to the
mechanism underlying this lethality, however, could only be
understood after the discovery of RLR signaling. In 2009, Hartner
and colleagues found that the mortality in Adar−/− embryonic
mouse model was associated with the overexpression of IFN
(44), and three studies in 2014–2015 showed that lethality can
be rescued to live birth by deleting either Mavs or Mda5 as well
(13, 15, 16). In contrast, Rig-I deletion did not rescue lethality
and inflammatory responses of Adar−/− embryos (16). These
findings indicated that in mice ADAR1 is able to block signaling
through the MDA5-MAVS axis of the type I IFN signaling
pathway, and that MDA5 is stimulated by endogenous dsRNA
in ADAR1’s absence. Knock-in of an editing-deficient form of
ADAR1 did not rescue lethality, indicating that the enzymatic
activity is crucial for survival (15). While Rig-I deletion in mice
did not rescue embryonic lethality, several in vitro studies in
mice and human cells have suggested that RIG-I activation is also
blocked by ADAR1 (45–47). Notably, Yang et al. (45) described
that the inhibitory effect of ADAR1 on RIG-I was mediated
through RNA binding rather than editing activity. Differences
in cell types, including HEK-293T cells, murine embryonic cells,
macrophages, and hepatocytes may explain this discrepancy, as it
is likely that the involvement of ADAR1 in RLR signaling is cell
type dependent.
The discussed findings indicate that the dampening of
RLR signaling is crucial to normal homeostasis and that
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endogenous RNA species can trigger RLRs in the absence of
ADAR1. In agreement with the embryonic Adar−/− mouse
model, naturally occurring mutations in ADAR1 were found
in humans with a severe and rare type I interferonopathy,
termed Aicardi Goutieres syndrome (AGS) (12, 14). AGS is a
fatal childhood encephalopathy characterized by uncontrolled
IFN expression and IFN presence in cerebral spinal fluid,
giving rise to symptoms reminiscent of a viral infection
(48–51). Mutations in MDA5 have also been found in AGS
patients (52, 53). These mutations were recently shown
to enhance MDA5 activity by increasing its efficiency in
recognizing dsRNA (54). A key question arose from this
work: “What endogenous ligand is recognized by RLRs
that triggers their activation in the absence of ADAR1 and
viral replication?”
With the development of deep-sequencing this question could
be addressed, for example by screening for editing sites globally.
Such efforts showed that mobile genetic elements termed Alu
repetitive elements, which can form dsRNA structures when
transcribed as inverted Alu repeats, are the most frequent
targets of A-to-I editing. Notably, Alu repeats are numerous:
there are more than 1 million of these repeats present in the
human genome, accounting for almost 11% of its size (55). Alu
repeats are likely to be selectively edited due to their secondary
structure and size, as ADAR1 editing does not require a strict
consensus sequence [reviewed by: (56)]. A-to-I editing in Alu
repeats disappears in ADAR1 knockout (KO) cells, possibly
providing an unedited, immunostimulatory dsRNA substrate for
RLR signaling (54, 57–71). Most of these Alu repeats are present
in introns and 3′ untranslated regions (UTRs) of mRNAs and
are transcribed by polymerase-II (54, 71). Mice do not possess
the primate-specific Alu repeats, but it is conceivable that other
mobile genetic elements capable of forming dsRNA, such as the
closely related rodent B1-SINE, could stimulate MDA5 in similar
ways if unedited. Additional substrates for ADAR1 editing
may be mitochondrial dsRNAs (mtdsRNAs), as it was recently
shown that patients with biallelic hypomorphic mutations in
the PNPT1 gene, which encodes polynucleotide phosphorylase
PNPase, contain mtdsRNAs in the cytoplasm that can activate
MDA5 and induce IFN (7). Deep-sequencing of PNPase depleted
cells revealed that mitochondrial RNAs were A-to-I edited.
Concurrent depletion of PNPase and ADAR1 enhanced IFN
expression, suggesting that ADAR1 editing of these endogenous
RNAs blocks IFN activation. Editing of host dsRNAs could
differentiate them from viral RNAs by altering their secondary
structure to abrogate the formation of extended dsRNA duplexes,
preventing IFN activation in uninfected cells (72). Alternatively,
edited dsRNA could act as an active inhibitor of IFN signaling.
Vitali et al. (73) found that extensively edited dsRNA (IU-
dsRNA) inhibits activation of the IFN pathway induced by the
dsRNAmimic polyriboinosinic:polyribocytidylic acid (poly(I:C))
in vitro. As a mechanism the authors proposed that IU-dsRNA
could bind to RLRs with higher affinity than poly(I:C), thereby
preventing their activation. Mapping of A-to-I editing sites have
shown that editing can be highly concentrated providing a source
of the potential IFN-inhibitory IU-dsRNA in vivo (15). These
data might indicate that ADAR1 is required to provide the cell
with a ligand that actively inhibits IFN signaling (and possibly
other cytoplasmic antiviral responses), a hypothesis that deserves
continued investigation.
ADAR1 BLOCKS PKR-INDUCED
TRANSLATION ARREST
A protein that is similar to ADAR1 in terms of its induction
by IFN and presence of multiple dsRBDs, is the IFN inducible
double-stranded RNA-activated protein kinase (PKR). PKR
is one of the best-studied ISGs and its expression inhibits
the replication of a wide range of viruses (74). It is also
antagonized by several viruses, including influenza A virus,
vaccinia virus and Ebola virus. It is a member of the eIF2α
family of protein kinases that also includes the PKR-like
endoplasmic reticulum kinase (PERK), the general control non-
depressible 2 kinase (GCN2) and the hemin-regulated inhibitor
of translation (HRI). Each of these kinases is activated under
different conditions of cellular stress, which is cytoplasmic
dsRNA in the case of PKR. Substrate recognition leads
dimerization via its dsRBDs (75, 76), autophosphorylation
and subsequent phosphorylation of eIF2α (77, 78), which
shuts down 5′-cap-dependent mRNA translation to prevent
viral protein synthesis (79, 80). This is accompanied by
the formation of cytoplasmic stress granules (SGs), dense
aggregations of RNA and proteins that store stalled translation
pre-initiation complexes.
Besides its function in dampening IFN induction, ADAR1
is also known to block translation arrest and stress granule
formation by inhibiting PKR activation (81–86). Several studies
have shown that ADAR1 functions in a proviral manner via
RNA editing and inhibiting PKR. Examples include measles
virus (MV) (83), vesicular stomatitis virus (VSV) (81, 85),
and human immunodeficiency virus (HIV) (82, 87, 88). In
these cases, ADAR1 is able to block PKR and this inhibition
was found to occur through both editing-dependent and
independent mechanisms. For MV, ADAR1-deficiency was
shown to lead to elevated cytotoxicity and apoptosis upon
virus infection, while viral replication was decreased (83).
Moreover, PKR activation observed in ADAR1 knockdown
(KD) cells upon MV infection was not rescued by an editing
deficient form of p150, indicating that for MV PKR inhibition
is editing-dependent (89). In contrast, during VSV and HIV
infection, ADAR1’s inhibitory effect on PKR was found to
occur in an editing-independent fashion (81, 82). In the
case of HIV, an increased interaction between ADAR1 and
PKR was observed during infection, which could represent
competition between both proteins for the same substrate, or
could indicate that ADAR1 directly interacts with PKR to
prevent its dimerization and subsequent autophosphorylation.
Complex formation between ADAR1 and PKR is independent
of RNA and the first dsRBD of ADAR1 is required for the
binding (81). By interfering with the activation of PKR, ADAR1
prevents the phosphorylation of eIF2α and the formation
of SGs, and consequently allows the translation of viral
mRNAs (81, 83–85).
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The observation that Mavs and Adar1 double knockout
(DKO) mice still die shortly after birth suggests that the lethality
of Adar1−/− mice is not solely reliant on IFN induction.
Suppressing PKR may also be required for survival, even in the
absence of viral infection. Interestingly, a recent study sheds
more light on this (71). In this study, ADAR1 KO (either
ADAR1 or ADAR1 p150) was shown to decrease protein, but
not mRNA, levels of several ISGs following IFN treatment. This
was associated with PKR and eIF2α phosphorylation upon IFN
treatment in KO, but not in wild-type (WT) cells. Furthermore,
PKR KD in ADAR1 KO cells partially restored ISG protein
levels, indicating that PKR activation in ADAR1 KO cells is
responsible for the lack of ISG protein expression. Intriguingly,
in IFN-treated ADAR1 KO cells, phosphorylated PKR levels were
significantly reduced by transcription inhibition, suggesting that
an endogenous RNA species, transcribed in response to IFN, is
responsible for the activation of PKR in these cells. In this same
study, it was found that >90% of A-to-I editing takes place in
Alu repeats, suggesting that ADAR1 editing or binding inhibits
them from activating PKR. Altogether, these results indicate that
ADAR1 is required for maintaining efficient translation during
the IFN response and that endogenous RNA transcripts activate
PKR in ADAR1’s absence. The endogenous RNA species that
activate PKR could be the same RNAs that activate MDA5 in the
absence of ADAR1, but this remains to be tested.
The relevance of the findings by Chung and colleagues was
further underlined by generating ADAR1 KO human embryonic
stem cells (hESC). While this genetic permutation was not
lethal to these hESCs, they did exhibit spontaneous MDA5-
mediated IFNβ production, PKR activation, and apoptosis upon
differentiation to neural progenitor cells (NPCs), indicating that
requirements for ADAR1-mediated PKR or MDA5 inhibition
depend on cell type or differentiation state. Also, the fact
that NPCs are more vulnerable to the effects of ADAR1
deficiency may indicate why AGS is associated with neurological
abnormalities. These results are in agreement with a study by
Yang and colleagues, in which ADAR1 KO was induced in
newborn mice. Upon sacrifice, these inducible ADAR1 KO mice
showed high levels of IFN specifically in neuronal tissues (45).
Unfortunately, neither studies showed whether the observed
effects were PKR- or MDA5-mediated.
In agreement with the finding that SGs can function as
platforms for RLR signaling (90), mounting evidence suggests
that PKR is also involved in the induction of type I IFN (91).
PKR may be involved in the activation of NFκB, a transcription
factor required for efficient IFN induction, possibly through
its interaction with the IKK complex (92). Moreover, PKR
was shown to bind members of the TRAF family, which are
involved in MAVS signaling (93). Further, several studies have
shown that PKR is required for IFN production in response to
poly(I:C) in vitro (94–97). PKR is also required for the production
of type I IFN in response to a subset of viruses, including
encephalomyocarditis virus, Theiler’s murine encephalomyelitis
virus, MV, West Nile virus, and Semliki forest virus, but not
influenza and Sendai virus (98–102). In addition, a recent
study showed that PKR interacts directly with MDA5 and
is able to enhance MDA5-mediated IFN production (103).
Efficient IFN induction required the catalytic activity of PKR,
but not the phosphorylation of eIF2α suggesting that these
effects are independent of the induction of SGs or translational
shutdown. Although ADAR1 is able to inhibit PKR activation,
the contribution of this inhibition to PKR-mediated type I IFN
induction remains to be determined.
ADAR1 BLOCKS THE OAS-RNASE L
PATHWAY
The IFN-inducible oligoadenylate synthetase (OAS)-RNase L
pathway is activated upon sensing of dsRNA. OAS proteins
(OAS1, OAS2, OAS3) produce 2′,5′-oligoadenylates (2-5A) upon
dsRNA recognition. This second messenger activates RNase L by
binding with high affinity to the inactive, monomeric form of
RNAse L, causing it to dimerize into its enzymatically active state
(104). In this state it is able to cleave both viral and host ssRNA,
predominantly after UpU and UpA dinucleotides, leaving a
5′OH and a 2′,3′-cyclic phosphate on the cleavage products
(105). RNAse L activation can lead to translation arrest through
cleavage of ribosomal RNA and mRNA (79, 106), autophagy
(107, 108), and apoptosis (109–111), preventing viral replication,
and spread.
A recent study reported that the cell-lethal phenotype of
ADAR1 deletion in human lung adenocarcinoma A549 cells was
rescued by RNASEL KO. This indicated that the OAS/RNase L
pathway is the primary mechanism that leads to cell death in
these cells, in the absence of ADAR1 and even in the presence
of MDA5 and MAVS (112). Furthermore, ectopic expression of
active, but not inactive, RNase L, in ADAR1/RNASEL DKO cells
promoted cell death, which supports the central role of RNase
L activation in dsRNA-mediated cell death in this cell line. In
addition, IFN-induced 2-5A accumulation was higher RNASEL-
ADAR1 DKO cells than inWT and RNASEL KO cells, indicating
that ADAR1 prevents the activation of OAS. Moreover, these
results suggest that ADAR1 is the primary regulator of RNAse
L activation in this cell type, most likely by preventing OAS
activation. Whether these data could be extrapolated to other
cell lines or even the entire organism remains to be tested, but
RNase L-mediated cell death in the absence of ADAR1 could
potentially contribute to AGS. Furthermore, the findings in Adar
andMavs/Mda5DKOmice and in ADAR1KONPCs suggest that
not the OAS-RNAse L but the RLR signaling pathway leads to cell
death in absence of ADAR1. Although it is uncertain at present
which pathways downstream of RLR signaling are mediating
lethality, these data indicate that the OAS-RNAse L pathway be
an important mediator of cell death.
ADAR1 AND VIRUSES
A bias toward A-to-G and U-to-C mutations has been described
for a wide range of genetically diverse viruses, suggestive of
ADAR editing (113). This could potentially lead to the synthesis
of dysfunctional viral proteins and RNA structures. Although
several studies have reported high editing levels that suggest a
mutagenic and antiviral role for ADAR1 (113), evidence of an
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important role for ADAR1 as part of the innate immune response
against virus infections is lacking. Additionally, studies that have
observed hypermutation have not yet shown, for example using
genetic KOs, that a specific ADAR protein is responsible for
editing, nor have they shown that editing itself leads to decreased
virus replication. Furthermore, it must be noted that for many
viruses it may not be possible to distinguish between the editing
of replication-competent viruses and defective interfering (DI)
viral genomes, which may be edited frequently (114–116). While
editing of viral genomes could decrease infectivity, editing of
DI viral genomes may prevent these from activating the innate
immune system. Inhibition of ADAR editing has been reported
for adenovirus and Vaccinia virus gene products, but it is yet
unknown whether RNAs encoded by these DNA viruses are
edited by ADARs. The adenovirus-associated (VAI) RNA is
responsible for ADAR1 inhibition and interestingly it is also is
capable of blocking both PKR and IFN induction (117–119).
RNA binding by PKR is generally an activatory signal, but VAI
RNA binding to PKR and ADAR1 is thought to sterically inhibit
homodimerization and activation (119–121). The vaccinia virus
E3L protein like ADAR1 contains a Z-DNA binding domain next
to a dsRBD and also blocks IFN induction, PKR, and ADAR1
(95, 121, 122). Notably, viral ADAR1 inhibition could be a
by-product of shielding or sequestering dsRNAs from antiviral
PRRs, like PKR, OAS, RIG-I, and MDA5.
ADAR1’s dampening effects on antiviral systems and its
proviral role during the replication of a wide range of viruses
(81–83, 85, 87, 88) suggest that there may also be viruses that
have evolved to usurp ADAR1 for their replication. In agreement,
a recent study showed that the influenza A virus NS1, and dengue
virus NS3 can bind ADAR1 and enhance its editing function,
although editing of viral genomes was not investigated (123).
As these proteins are also capable of blocking IFN induction,
this raises the question whether IFN-inhibition is dependent
on ADAR1. The modulation of ADAR1 by viruses underlines
the importance of this protein in innate immunity and viral
replication, although it must be noted that none of these gene
products have been demonstrated to alter A-to-I editing through
direct agonism or antagonism of ADAR1 during infection.
ADAR1 AND CANCER
Recent advances in the field point toward an important role
for ADAR1 in tumorigenesis [reviewed in: (124, 125)]. In most
tumor types, RNA editing levels are elevated compared to
matched normal tissues, suggesting that editing may supplement
genomic DNA alterations and drive tumorigenesis (70). Editing
in coding regions of certain mRNAs has been associated with
oncogenic activity by giving rise to amino acid changes that
alter protein properties (70, 124, 126–129). For example, during
esophageal squamous cell carcinoma progression editing of the
Antizyme inhibitor 1 mRNA increases, leading to a serine
to glycine change that affects cellular polyamine levels. In
addition, ADAR1 can also edit microRNAs (miRNAs), which
could inhibit their processing or lead to retargeting (130–133).
For example, miR-200b was found to be overedited in multiple
cancer types, leading to retargeting to the tumor suppressor
leukemia inhibitory factor receptor. Editing levels of miR-200b
were found to correlate with poor patient survival. In another
study, ADAR1 editing was found to reduce levels of the tumor
suppressing let-7 family of miRNAs, leading to enhanced self-
renewal of leukemic stem cells (132). Besides direct effects on
miRNA function through editing, ADAR1 has also been shown to
interact directly with Dicer to promote processing of siRNAs and
miRNAs, RISC loading of miRNAs, and consequently silencing
of target RNAs (134). Notably, these effects were independent
of ADAR1 editing. These data indicate that loss of ADAR1
could result in dysregulated expression of many genes, which
are otherwise silenced by miRNAs. Although ADAR1 is likely to
contribute to tumorigenesis by altering gene expression through
editing dependent and independent mechanisms, ADAR1 has
recently also been shown to contribute to tumorigenesis through
its role as regulator of innate immunity.
As reviewed extensively by Parker et al. (135), type I IFNs have
important antitumor effects, such as the induction of apoptosis
and attraction of infiltrating immune cells. Therefore, malignant
cells with dysfunctional IFN responses have a selective advantage.
Moreover, the loss of IFN defenses is thought to form the basis
for the cancer selectivity of several oncolytic viruses (136). Three
recent studies have shown that deleting ADAR1 in tumor cells
can induce lethality (137–139). Removal of ADAR1 also rendered
these cells more vulnerable to immuno-therapy and overcame
resistance to checkpoint blockade, pinpointing ADAR1 as a new
immuno-oncology target (138). Interestingly, the lethality of
ADAR1 KO tumor cells was rescued by PKR deletion, which
is distinct from the embryonic lethality phenotype observed in
Adar1–/– mice which was mediated through the MDA5/MAVS
pathway (13, 15, 16). In another study, lethality of A549 ADAR1
KO cells was mediated through the OAS/RNAse L pathway (112).
These data indicate that downstream pathways that mediate
FIGURE 2 | ADAR1’s dampening effect on immune activity prevents
autoimmunity in steady-state, but should be regulated during viral infection.
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cellular lethality after ADAR1 deletion may depend on the cell
type, developmental stage, and/or malignant nature of the cells
under investigation. However, the loss of ADAR1, either in
normal or malignant cells, will lead to the accumulation of
unedited endogenous dsRNAs, which trigger cytoplasmic dsRNA
sensors. Malignant cells may have elevated levels of unedited
dsRNAs due to the loss of suppressive epigenetic modifications
in repeat regions, genomic instability or mitochondrial damage
due to oxidative stress (140–142), which would select for cells that
have higher editing activities. While the activation of cytoplasmic
innate immune sensors is normally deleterious, it may be
beneficial in the context of cancer treatment by initiating IFN
signaling in the tumor microenvironment. Exploitation of this
mechanism through intratumoral ADAR1 inhibition or oncolytic
virus therapy using viruses that (naturally) encode ADAR1
inhibitors may be promising candidates for cancer treatment.
ADAR1 REGULATION
The fact that ADAR1 inhibits canonical antiviral pathways in
steady-state raises the question: “How does the host overcome
this inhibition during viral infection in order to mount an
effective antiviral response?” (Figure 2). Although this question
is currently under extensive investigation, several lines of
evidence suggest that ADAR1 activity is tightly controlled
in the cell. The promoter responsible for p150 expression
possesses a consensus interferon-stimulated response element
(ISRE) characteristic of ISGs (33, 35, 40). In steady-state cells
generally express low levels of p110 and p150. These levels may
not be capable of editing the large amounts of viral dsRNA
intermediates generated during replication, which would leave
unedited substrates to be recognized by PRRs once the dsRNA
levels exceed a certain threshold. However, as transcription is a
relatively slow process other, more rapid, regulatory mechanisms
are likely to be in place.
Besides regulation at the transcriptional level by IFN, ADAR1
appears to act as a dimer and dimerization can contribute
to regulating editing activity and substrate specificity (143,
144). The minimum region required for the dimerization
of Drosophila ADAR is the N-terminus including and the
first dsRBD (144). Although the exact region required for
dimerization of human ADAR is not known yet, the dsRBDs
are likely to be involved as these domains often regulate protein
dimerization (78, 145). Considering that ADAR1 can bemodified
by SUMO-1 in a region between the Z-DNA and first dsRBD and
that this modification decreases editing activity, it is hypothesized
that the SUMO modification sterically hinders dimerization, or
interferes with substrate binding (146).
Another post-translation modification that affects ADAR1
function is ubiquitination. IFN signaling was shown to promote
the Lys-48 mediated ubiquitination and degradation of p110
FIGURE 3 | ADAR1 balances self-tolerance and immune activity by modulating canonical antiviral pathways induced by dsRNA. (A) Adenosine to inosine editing or
binding of the cytoplasmic ADAR1 isoform p150 or the nuclear p110 to extended dsRNA duplexes prevents their detection by cytoplasmic antiviral signaling
pathways, including RIG-I like receptor-, OAS/RNAseL-, and PKR pathways. These dsRNA duplexes can be of viral origin, but in the absence of ADAR1
(B) endogenous dsRNAs—which are likely to originate from inverted Alu repeats or other sources (e.g., mitochondrial dsRNAs)—can also serve as a substrate for
antiviral signaling, leading to immune activation, and possibly autoimmunity. Blocking the activation of these pathways prevents IFN-I production, translation arrest,
and apoptosis, but this must be tightly regulated in order to not create an environment that favors virus replication.
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(147). Critically, this down-regulation was shown to be required
for IFN signaling to execute efficient antiviral activity during
VSV infection, suggesting that the cell needs to bypass the
constant inhibitory effect of ADAR1 on IFN signaling in order
to achieve an effective antiviral response. As p110 is largely
absent from the cytoplasm, these data might suggest that newly
transcribed unedited endogenous dsRNAs, exported from the
nucleus into the cytoplasm, are involved in mounting a robust
IFN response. It is tempting to speculate that these endogenous
RNAs help stabilize RLR signaling complexes without requiring
large amounts of harmful viral dsRNA.
Another mechanism by which ADAR1 could be modulated
during viral infection is by regulating the availability of a free
inositol pyrophosphate (IP6). IP6 may regulate ADAR1 as it is
an essential cofactor for human ADAR2 and has been found
buried within the enzyme core of the enzyme (148). In addition,
most of the IP6 contact residues are conserved between human
ADARs, and yeast ADAT1, a member of a family of related
adenosine editing enzymes that act on transfer RNA (tRNA)
also relied on IP6 for tRNA editing. Interestingly, a recent study
that employed a human genome-wide RNA interference screen
identified an essential role for inositol pyrophoshates in the type
I IFN response as the activities of the inositol polyphosphate
kinases, IPPK, PPIP5K1, and PPIP5K2 (which convert IP5 to IP6
and 1-IP7) were crucial for interferon induction and the control
of Sendai and influenza A viruses (149). Whether this is linked to
ADAR1 activity remains to be tested.
Altogether, these data indicate that ADAR1 activity can be
controlled rapidly through protein-protein interactions, post-
translational modifications, or the availability of cofactors.
Downmodulation of ADAR1 activity may be expected early
in infection to mount an effective IFN response, but later
in infection an increase in ADAR1 activity may be necessary
to prevent apoptosis in certain cell types. The discovery of
novel mechanisms that regulate ADAR1 activity will be highly
interesting for the treatment of viral infections, cancer, and
autoimmune diseases.
CONCLUDING REMARKS
Extended, perfectly matching dsRNA duplexes are unusual in
eukaryotic cells and are indicative of viral replication or the
expression of endogenous mobile genetic elements. Sensory
systems have evolved to respond to dsRNA. For example, the
RLR signaling, PKR, and OAS-RNAse L systems all act as
sensors and/or effectors in the response to dsRNA. Findings from
studies over the past decade or so indicate that these pathways
are all regulated by ADAR1 (Figure 3), which was originally
discovered for its ability to unwind dsRNA structures. Although
the mechanisms behind ADAR1’s regulation of these pathways
are currently under extensive investigation, it is likely that there
are both editing-dependent and-independent mechanisms. The
importance of ADAR1 in maintaining homeostasis is underlined
by the severe autoimmune phenotype of AGS patients, which can
be recapitulated through homozygous deletion of Adar1 in mice.
In agreement, recent advances confirm that the main function
of ADAR1 seems to be to prevent self RNAs from triggering
immune responses. Themajority of these RNAs is likely to consist
of Alu repeats, although the conceptual distinction between self
and non-self seems to be complicated by such mobile genetic
elements. Intriguingly, these repeats may be beneficial to their
host by accelerating host evolution (150), and it seems that
expression of ADAR1 allows us to live together with these
selfish elements by blocking their intrinsic immunostimulatory
molecular patterns. These molecular patterns are also present
in viruses, which calls for the need for a tight regulation on
A-to-I editing in order to not predispose the host for viral
infections. In accordance, dysregulation of ADAR1 may play an
important role in viral pathogenesis. In addition, these molecular
patterns may be elevated in malignant cells, which may explain
why these cells have higher editing activities. This could render
malignant cells susceptible to cell death by ADAR1 inhibition
and could pinpoint ADAR1 as a new target in immuno-
oncology. Continued investigation of the function and regulation
of ADAR1 will help identify mechanisms regulating the balance
between immune activity and self-tolerance.
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